LoadingLoadingLoading35 funds hold it.Insiders net selling.
Net selling: insiders sold $8.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 30, 2026
Financial period
Third-Quarter 2026
Earnings per share
$3.76 expected
Revenue
$17.35B expected
Estimates as of Nov 5, 2026
EPS expected
$3.84 to $4.01
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 30, 2026 | $3.82est. $3.76 | +1.47%beat | $17.40Best. $17.35B+0.33% | +10.3%from $15.78B |
| Jun 30, 2026Reported Jul 31, 2026 | $3.65est. $3.61 | +1.15%beat | $16.99Best. $16.76B+1.36% | +10.2%from $15.42B |
| Mar 31, 2026Reported Apr 29, 2026 | $2.65est. $2.67 | -0.77%in line | $15.00BSEC filing | +12.4%from $13.34B |
| Dec 31, 2025Reported Feb 4, 2026 | $2.71est. $2.65 | +2.16%beat | $16.62BSEC filing | +10.0%from $15.10B |
| Sep 30, 2025Reported Oct 31, 2025 | $1.86est. $1.78 | +4.49%beat | $15.78BSEC filing | +9.1%from $14.46B |
| Jun 30, 2025Reported Jul 31, 2025 | $2.97est. $2.91 | +2.06%beat | $15.42BSEC filing | +6.6%from $14.46B |
| Mar 31, 2025Reported Apr 25, 2025 | $2.46est. $2.40 | +2.50%beat | $13.34BSEC filing | +8.4%from $12.31B |
| Dec 31, 2024Reported Jan 31, 2025 | $2.16est. $2.12 | +1.89%beat | $15.10BSEC filing | +5.6%from $14.30B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.62B | $15.00B | $16.99B | $17.40B |
| Cost of what it sold | $4.55B | $4.22B | $4.29B | $2.62B |
| Gross profit | $12.07B | $10.78B | $12.70B | $14.79B |
| What it spent | ||||
| Research and development | $2.58B | $2.47B | $2.34B | $2.57B |
| Sales and admin | $3.90B | $3.58B | $3.63B | $4.09B |
| Other operating costs | -$217.0M | — | $291.0M | $1.65B |
| Total operating expenses | $6.26B | $6.05B | $6.27B | $8.30B |
| What was left | ||||
| Operating profit | $5.81B | $4.73B | $6.43B | $6.48B |
| Interest on debt | $714.0M | $717.0M | $746.0M | $700.0M |
| Profit before tax | $2.67B | $1.04B | $4.28B | $4.83B |
| Tax | $853.0M | $342.0M | $662.0M | $609.0M |
| Net profit | $1.82B | $699.0M | $3.61B | $4.22B |
| EBITDA | $5.37B | $3.69B | $8.61B | $6.48B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
AbbVie stock hits all-time high at 298.74 USD
NeutralNov 5Regenxbio Q3 2026 Earnings Call Transcript
BullishNov 5What Could AbbVie Stock Be Worth In Three Years?
Leans bullishNov 5Alzheimer’s Data Update Could Be A Key Test For Biogen Stock (BIIB)
NeutralNov 5Is Incyte (INCY) Undervalued On Trial Progress And Raised Sales Guidance?
Leans bullishNov 5LTC Properties (NYSE:LTC) Now Covered by Analysts at Huntington
NeutralNov 5Nxera's gut-targeted molecule nets $1.47bn from AbbVie
BullishNov 5What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Nov. 3
Leans bullishNov 5
